Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 4Biopsy 4Whole-Body Irradiation 3Mycophenolic Acid 3Cyclosporine 3Cyclophosphamide 3fludarabine phosphate 2decitabine and cedazuridine drug combination 2Sirolimus 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Busulfan 2venetoclax 1tocilizumab 1ruxolitinib 1peginterferon alfa-2b 1iadademstat 1fludarabine 1Tacrolimus 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Idarubicin 1Hyperbaric Oxygenation 1Filgrastim 1Etoposide 1Cytarabine 1Cyclosporins 1Cord Blood Stem Cell Transplantation 1Clofarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × iadademstat × 30 days × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡